Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

NCT07093411 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

48

Enrollment

OTHER

Sponsor class

Conditions

B-cell Non-Hodgkin Lymphoma Recurrent B-cell Non-Hodgkin Lymphoma Refractory

Interventions

BIOLOGICAL: LUCAR-E9D or LUCAR-E9K cells product

Sponsor

Beijing GoBroad Hospital

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]